The Hindu·3 min read·medium

Sun Pharma gets Brazil nod for Semaglutide

N
N. Ravi Kumar
Sun Pharma gets Brazil nod for Semaglutide
AI Summary

Sun Pharma has received regulatory approval in Brazil to manufacture and market generic semaglutide for type 2 diabetes. This expansion follows the company's recent launch of the drug in South Africa and India.

Sun Pharmaceutical Industries has received Brazilian Health Regulatory Agency ANVISA approval to manufacture and market semaglutide injection in the Latin American country.

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
businesshealth

Get the full story

Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.

Create free account

Already have an account? Sign in